Emerging Personalized Opportunities for Enhancing Translational Readthrough in Rare Genetic Diseases and Beyond
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24076101 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Roland N Wagner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria. Hauptthemen laut MEDLINE: Codon, Nonsense, Genetic Diseases, Inborn, Peptide Chain Elongation, Translational, Precision Medicine. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helga Kellerhals Foundation, Land Salzburg WISS 2025 Research Initiative Grant, Hans-Gröber-Stiftung Vaduz.
Abstract (Originalsprache)
Nonsense mutations trigger premature translation termination and often give rise to prevalent and rare genetic diseases. Consequently, the pharmacological suppression of an unscheduled stop codon represents an attractive treatment option and is of high clinical relevance. At the molecular level, the ability of the ribosome to continue translation past a stop codon is designated stop codon readthrough (SCR). SCR of disease-causing premature termination codons (PTCs) is minimal but small molecule interventions, such as treatment with aminoglycoside antibiotics, can enhance its frequency. In this review, we summarize the current understanding of translation termination (both at PTCs and at cognate stop codons) and highlight recently discovered pathways that influence its fidelity. We describe the mechanisms involved in the recognition and readthrough of PTCs and report on SCR-inducing compounds currently explored in preclinical research and clinical trials. We conclude by reviewing the ongoing attempts of personalized nonsense suppression therapy in different disease contexts, including the genetic skin condition epidermolysis bullosa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria.
- Department of Biosciences, University of Salzburg, 5020 Salzburg, Austria.
ORCID-Profile: Roland N Wagner, Johanna Zandanell
Förderung
- Helga Kellerhals Foundation
- Land Salzburg WISS 2025 Research Initiative Grant
- Hans-Gröber-Stiftung Vaduz
- Maestro Mandozzi Foundation Locarno/Salzburg
Zitieren
APA
Wagner, R. N., Wießner, M., Friedrich, A., Zandanell, J., Breitenbach-Koller, H., & Bauer, J. W. (2023). Emerging Personalized Opportunities for Enhancing Translational Readthrough in Rare Genetic Diseases and Beyond. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076101
Vancouver
Wagner RN, Wießner M, Friedrich A, Zandanell J, Breitenbach-Koller H, Bauer JW. Emerging Personalized Opportunities for Enhancing Translational Readthrough in Rare Genetic Diseases and Beyond. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076101
BibTeX
@article{Wagner2023,
author = {Wagner, Roland N and Wießner, Michael and Friedrich, Andreas and Zandanell, Johanna and Breitenbach-Koller, Hannelore and Bauer, Johann W},
title = {Emerging Personalized Opportunities for Enhancing Translational Readthrough in Rare Genetic Diseases and Beyond},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24076101}
}
EUVIMED